90y ibritumomab tiuxetan

نتایج جستجو برای: 90y ibritumomab tiuxetan

تعداد نتایج: 879 فیلتر نتایج به سال:

Recommendations for the use of Yttrium-90 ibritumomab tiuxetan in malignant lymphoma

Journal: :Cancer 2006

متن کامل

Mantle cell lymphoma initial therapy with abbreviated R-CHOP followed by 90Y-ibritumomab tiuxetan: 10-year follow-up of the phase 2 ECOG-ACRIN study E1499

Journal: :Leukemia 2016

متن کامل

Myeloablative doses of yttrium-90-ibritumomab tiuxetan and the risk of secondary myelodysplasia/acute myelogenous leukemia.

Journal: :Cancer 2011

Anna Guidetti Carmelo Carlo-Stella Marco Ruella Rosalba Miceli Lilli Devizzi Silvia L Locatelli Arianna Giacomini Adele Testi Stefano Buttiglieri Alessandra Risso Luigi Mariani Massimo Di Nicola Roberto Passera Corrado Tarella Alessandro M Gianni

BACKGROUND Because the long-term toxicity of myeloablative radioimmunotherapy remains a matter of concern, the authors evaluated the hematopoietic damage and incidence of secondary myelodysplastic syndrome and acute myelogenous leukemia (sMDS/AML) in patients who received myeloablative doses of the radiolabeled antibody yttrium-90 (⁹⁰Y)-ibritumomab tiuxetan. METHODS The occurrence of sMDS/AML...

متن کامل

Phase II Trial of Short-Course R-Chop Followed by 90Y-Ibritumomab Tiuxetan in Previously Untreated High-Risk Elderly Diffuse Large B-Cell Lymphoma Patients

Journal: :Clinical Cancer Research 2010

متن کامل

Long-Term Follow-Up of 90Y-Ibritumomab Tiuxetan, Fludarabine, and Total Body Irradiation–Based Nonmyeloablative Allogeneic Transplant Conditioning for Persistent High-Risk B Cell Lymphoma

Journal: :Biology of Blood and Marrow Transplantation 2018

متن کامل

The Novel Expanded Porphyrin, Motexafin Gadolinium, Combined with [90Y]Ibritumomab Tiuxetan for Relapsed/Refractory Non-Hodgkin's Lymphoma: Preclinical Findings and Results of a Phase I Trial

Journal: :Clinical Cancer Research 2009

متن کامل

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید

Recommendations for the use of Yttrium-90 ibritumomab tiuxetan in malignant lymphoma

Mantle cell lymphoma initial therapy with abbreviated R-CHOP followed by 90Y-ibritumomab tiuxetan: 10-year follow-up of the phase 2 ECOG-ACRIN study E1499

Myeloablative doses of yttrium-90-ibritumomab tiuxetan and the risk of secondary myelodysplasia/acute myelogenous leukemia.

Radioimmunotherapy for B-cell lymphoma: Y90 ibritumomab tiuxetan and I131 tositumomab

Ibritumomab tiuxetan (Zevalin) and elevated serum human anti-murine antibody (HAMA)

Ibritumomab tiuxetan plus BEAM in refractory diffuse large B-cell lymphoma

Yttrium-90 ibritumomab tiuxetan in the treatment of non-Hodgkin lymphoma

Phase II Trial of Short-Course R-Chop Followed by 90Y-Ibritumomab Tiuxetan in Previously Untreated High-Risk Elderly Diffuse Large B-Cell Lymphoma Patients

Long-Term Follow-Up of 90Y-Ibritumomab Tiuxetan, Fludarabine, and Total Body Irradiation–Based Nonmyeloablative Allogeneic Transplant Conditioning for Persistent High-Risk B Cell Lymphoma

The Novel Expanded Porphyrin, Motexafin Gadolinium, Combined with [90Y]Ibritumomab Tiuxetan for Relapsed/Refractory Non-Hodgkin's Lymphoma: Preclinical Findings and Results of a Phase I Trial